Cboe BZX Shakes Up Crypto Markets with Bold Injective & Solana ETF Filings
Wall Street's playing catch-up—again. Cboe's BZX exchange just lobbed a grenade into traditional finance with dual ETF filings targeting two of crypto's hottest protocols: Injective and Solana.
Injective's institutional moment
The derivatives-focused blockchain gets its mainstream close-up. Institutional money's about to flood into INJ's hyper-efficient trading infrastructure—whether old-school traders understand it or not.
Solana's revenge tour continues
SOL's 2024 comeback reaches its logical conclusion. After surviving the FTX wreckage, this filing proves Solana's Layer 1 isn't just surviving—it's being institutionalized.
Regulatory roulette ahead
Expect the SEC to drag its feet while VCs quietly position themselves. Because nothing moves faster than Wall Street chasing 20-somethings' blockchain innovations—except maybe their compliance departments hitting the brakes.
U.S. Dollar Comes Onchain as GENIUS Act Ushers in Digital Era
Both ETF proposals were submitted using the SEC’s standard two-step process, which includes an initial 19b-4 filing by the exchange followed by a corresponding S-1 or trust registration by the sponsor. These filings are the formal beginning of the regulatory review cycle.
The simultaneous filings for both INJ and SOL ETFs reflect a broader shift in the crypto investment landscape, as asset managers race to bring new blockchain-native assets into the traditional financial system through compliant, exchange-traded structures.
